--- title: "Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/282553850.md" description: "Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News" datetime: "2026-04-13T05:35:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282553850.md) - [en](https://longbridge.com/en/news/282553850.md) - [zh-HK](https://longbridge.com/zh-HK/news/282553850.md) --- # Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News ### Related Stocks - [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) ## Related News & Research - [Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data](https://longbridge.com/en/news/285400985.md) - [BioRestorative reports Phase 2 BRTX-100 data showing 52% hit pain, function endpoint](https://longbridge.com/en/news/285584056.md) - [Verrica To Present Positive Phase 2 Data For VP-315 In Treating Basal Cell Carcinoma At SID Meeting](https://longbridge.com/en/news/285349672.md) - [16:01 ETInnocan Pharma LPT-CBD is featured in Pain Medicine News](https://longbridge.com/en/news/285427579.md) - [NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating](https://longbridge.com/en/news/285267932.md)